For weight, the premium buys something measurable. Indirect comparison puts tirzepatide 10 mg and 15 mg ahead of semaglutide by 4.85 and 6.26 percentage points. For heart attacks and strokes it buys nothing measurable. The one direct comparison returned a hazard ratio of 1.06, with an interval spanning no difference. No randomized trial has compared the two molecules head to head for weight loss at all.
The premium also buys a different stopping problem. Tirzepatide is the drug with the most to lose when a course ends, and most courses end inside a year.
Tirzepatide costs more than semaglutide almost everywhere, and the question worth asking is what the extra money is buying. Across the sellers this desk tracks, the median published tirzepatide figure is $249 a month against $179 for semaglutide. That is a premium of $70, or 39 per cent. The evidence on whether that is worth paying comes in two pieces that answer different questions, and they are routinely quoted as though they were one. The full price distribution shows how much that premium varies by seller.
On weight, the comparison is indirect
There is no randomized trial that put tirzepatide against semaglutide for weight loss. What exists is a Bayesian network meta-analysis that compared them through their shared placebo arms. After a heterogeneity assessment, six of 42 identified randomized trials were similar enough to include. Against semaglutide, tirzepatide 10 mg showed 4.85 percentage points more weight reduction and 15 mg showed 6.26 [1]. Waist circumference moved 4.81 and 5.32 cm further. The lower tirzepatide dose was broadly comparable to semaglutide, and safety profiles were described as generally similar.
On cardiovascular events, the comparison is direct — and null
Here the design is better and the answer is less flattering to the premium. A 2026 analysis of five cohort studies in US insurance data emulated two cardiovascular outcome trials to validate its method, then compared the molecules directly. For the composite of myocardial infarction, stroke or death, tirzepatide against semaglutide gave a hazard ratio of 1.06 (95% CI 0.95 to 1.18) [2]. That interval spans one in both directions: no measured difference.
The same work found semaglutide against sitagliptin at 0.82 (95% CI 0.74 to 0.91). It found tirzepatide against dulaglutide at 0.87 (95% CI 0.75 to 1.01). Both molecules look cardiovascularly useful. They just do not look different from each other.
What this means at the checkout
If the reason for choosing tirzepatide is more weight loss, the indirect evidence supports paying something for it at 10 mg and above. If the reason is a better cardiovascular outcome, the direct evidence does not support paying anything for it. A premium also only means something if it is the real premium. Several sellers on this market advertise one figure and bill another. The gap between molecules can be smaller or larger than the cards suggest.
Before deciding, check whether the tirzepatide rate you are quoted holds at a higher dose. The indirect advantage sits at 10 and 15 mg. That is where a dose-scaled price bites hardest. The seller comparisons show which pairs actually differ on this, and the price check will place a quote against the rest of the market.
Price figures are computed from this site’s own records at build time, most recently read September 2026, across 430 priced sellers. The clinical figures are cited.